Expanded Access: FDA To Clarify How Adverse Events Impact Drug Approval Process

GAO says lack of clear information from FDA may influence whether manufacturers grant expanded access to investigational drugs; only two clinical holds have been due to adverse events from expanded access use.

FDAEntrance_1200x675

The US Government Accountability Office (GAO) had only one recommendation for FDA after reviewing its expanded access program: the agency should clearly communicate how it uses adverse events data from the program in reviewing a drug for approval.

In a recent report, GAO said some manufacturers and other stakeholders contend that FDA is not clear about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership